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Accepted 11 March 2016; Published online 20 May 2016AbstractObjectives: Evaluate methodological advantages and limitations of an international pharmacosurveillance system based on electronic
health records (EHRs).
Study Design and Settings: Type 2 diabetes was used as an exemplar. Cohorts of newly treated diabetics were followed in each country
(Quebec, Canada; Massachusetts, United States; Manchester, UK) from 2009 to 2012 using local EHR systems. Cox proportional hazards
models were used to assess the risk of cardiovascular events.
Results: A total of 44,913 newly treated diabetics were identified; 82.6% (United States) to 93.1% (Canada) were started on biguanides;
13% of patients failed to fill initial prescriptions. An increased risk of cardiovascular events with sulfonylureas was observed when
dispensing [hazard ratio (HR): 2.83] vs. EHR prescribing (HR: 2.47) data were used. The addition of clinical data produced a threefold
to 10-fold increase in comorbidity for obesity and renal disease, but had no impact on the risk of different hypoglycemic therapies. The
risk of cardiovascular events with sulfonylureas was higher in the United States [HR: 3.4; 95% confidence interval (CI): 2.1, 5.5] compared
to England (HR: 1.3; 95% CI: 1.1, 1.6).
Conclusion: An international surveillance system based on EHRs may provide more timely information about drug safety and new
opportunities to estimate potential sources of bias and health system effects on drug-related outcomes.  2016 The Author(s). Published
by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Keywords: Pharmacosurveillance; Medication adherence; Electronic health record; Adverse outcome; Risk assessment; Health informatics;
Pharmacoepidemiology
1. IntroductionConflict of interest: There are no conflicts of interest.
Funding: This project was funded by the Canadian Institutes of Health
Research (CIHR) operating grant # 201009MOP. T.E. was supported by a
CIHR postdoctoral fellowship. W.G.D. was supported by a Medical
Research Council (MRC) Clinician Scientist Fellowship (G0902272).
* Corresponding author. McGill University, Morrice House, 1140 Pine
Ave West, Montreal, Quebec, Canada, H3A 1A3. Tel.: (514)-934-
1934x32999; fax: (514)-843-1551.
E-mail address: robyn.tamblyn@mcgill.ca (R. Tamblyn).
http://dx.doi.org/10.1016/j.jclinepi.2016.03.033
0895-4356/ 2016 The Author(s). Published by Elsevier Inc. This is an open ac
licenses/by-nc-nd/4.0/).Although an estimated $1.3 trillion will be spent world-
wide on drugs each year [1], there is limited capacity to
assess the comparative risks and effectiveness of medica-
tions after they enter the market [2e6]. In addition, even
when safety problems are identified, there is no timely or
effective method of reliably communicating this informa-
tion to physicians to inform prescribing decisions [7e9].
However, there are new opportunities to address both of
these problems. In the last 2 decades, the use of electronic
health records (EHRs) has increased steadily. In particular,cess article under the CC BY-NC-ND license (http://creativecommons.org/
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Key findings
 There is an increased risk of cardiovascular events
with sulfonylureas compared to biguanides, in the
United States compared to England.
 The prevalence of comorbiditiesdobesity, lipid
disorders, and renal diseasedmore than doubles
when clinical information is included in
measurement.
What this adds to what was known?
 Thirteen percent of patients newly started on oral
hypoglycemic therapy will not fill the initial pre-
scription; drug cost and copayment are health sys-
tem effects that may influence adherence.
What is the implication and what should change
now?
 Efforts to implement EHR standards nationally and
internationally should focus on semantic interopera-
bility for data required for international pharmacosur-
veillance: classification of prescription drugs,
adverse events, and therapeutic outcomes (e.g.,
HbgA1c).
 Evidence suggests that gliclazide may have a supe-
rior safety profile for the second-line management
of type 2 diabetes compared to other drugs, and
further research in this area with future real-
world trials would be beneficial.
many countries see computerizing drug management as a
priority because errors in medication use can be potentially
reduced by computerizing prescribing, dispensing, adminis-
tration, and information sharing [10e21]. One of the bene-
fits of the rise in EHR adoption is that it has catalyzed
global efforts to establish international clinical data classi-
fication and communication standards, and vendors of
health information technologies are encouraged to meet
these requirements [22e25]. This concerted international
investment creates an unprecedented opportunity to replace
antiquated systems of postmarket surveillance and risk
communication, with real-time monitoring and communi-
cation of the population experience with a particular drug
across multiple jurisdictions [21,26,27]. An international
surveillance system has great potential to provide timely
measurement of treatment effectiveness and detection of
adverse effects as tens of millions of new users could be
monitored, not only to assess the overall effects in the pop-
ulation, but to have the power and sufficient population het-
erogeneity to detect differences in safety and effectiveness
in genetic, ethnic, and clinically defined subpopulations
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the effects of treatment may vary by sex, race, and ethnicity
[30e35] likely because of subpopulation differences in the
prevalence of genetic polymorphisms that influence the
metabolism of medication and its efficacy and toxicity
[36,37]. Moreover, countries will vary in the introduction
and uses of new drugs, creating natural experiments to eval-
uate treatment effectiveness within therapeutic classes.
To effectively use these rich, multinational real-time
data resources we need to expand our knowledge on how
to use these data in epidemiologic contexts. Specifically,
for pharmacosurveillance, we need to evaluate potential
methodological advantages and limitations of using EHRs
for pharmacosurveillance, as well as the potential benefits
of assessing drug safety and effectiveness in different pop-
ulations and health systems.
In this study, we addressed two methodological issues
that are pertinent to the use of EHRs in comparison to
administrative data. First, we assessed the potential disad-
vantage of using prescriptions to measure drug exposure
rather than administrative records of dispensed medication,
misclassification that may bias estimates of safety and
effectiveness because of nonadherence to prescribed ther-
apy. The availability of linked electronic prescription and
dispensing data in one country enabled us to estimate the
incidence of primary nonadherence, the characteristics of
patients who failed to fill the initial prescription, and the
consequences of using prescribed vs. dispensed data on
the risk of adverse events. Second, one of the advantages
of EHRs is that they provide rich clinical data that can be
used to measure comorbidity such as laboratory and phys-
iologic measures. We used more detailed clinical data avail-
able in EHRs in three countries to estimate the extent of
misclassification of comorbidity and the impact of more ac-
curate measurement on the risk of adverse events.
We used type 2 diabetes and the risk of cardiovascular
events in relationship to oral hypoglycemics to assess these
methodological issues, as the risk associatedwith older prod-
ucts such as the sulfonylureas has been well characterized
[38e46] and could serve as a means of validating the results.
New hypoglycemics are also differentially entering these
markets providing an opportunity to use international sur-
veillance as a powerful means of assessing risk and benefit.2. Methods
2.1. Design and population
Three prospective cohorts of persons who were new
users of oral hypoglycemics between 2009 and 2012 were
assembled in Canada, England, and the United States from
local EHR systems. To be included in the cohort, individ-
uals had to be 18 years or older and be newly started on oral
hypoglycemic therapy, defined as having no prescription
for an oral hypoglycemic or insulin in the past 2 years.
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tional diabetes or polycystic ovarian syndrome, as these
conditions are also indications for biguanides. The occur-
rence of cardiovascular events [stroke and myocardial
infarction (MI)] was assessed before the start of treatment
as well as during follow-up, starting with the date of the
first oral hypoglycemic prescription to a maximum of
30 months.
2.2. Data sources
2.2.1. Quebec, Canada cohort
Data were extracted from the Medical Office of the 21st
Century (MOXXI) EHR that includes a real-time linkage to
the Quebec insurance agency, the Regie de l’assurance mal-
adie du Quebec databases, providing historical, and daily
updates of patients’ medical services received (diagnosis,
procedure, date, location, provider), prescriptions dispensed
from community pharmacies for persons who are publically
insured (prescriber, pharmacy, drug, dose, dispensing date,
duration, refills), and mortality. Approximately 110 primary
care physicians in Quebec use MOXXI for approximately
90,000 of their patients.
2.2.2. Boston, US cohort
Data were extracted from the Partners HealthCare
Research Patient Data Registry (RPDR). RPDR includes
data from the longitudinal medical record (LMR), an inter-
nally developed, web-based, fully functional EHR that was
in use during this period for the participating clinics from
Brigham and Women’s Hospital (BWH) and Massachusetts
General Hospital (MGH), the two founding members of
Partners Healthcare in Boston, Massachusetts. Data were
retrieved from the structured clinical encounter information
from RPDR. To ensure complete follow-up, patients were
eligible if they were seen in 1 of 37 BWH- or MGH-
affiliated primary care or diabetes clinics.
2.2.3. England cohort
Data were extracted from the CPRD (Clinical Practice
Research Datalink). CPRD is an anonymized LMRs data-
base for primary care. The primary care EHR includes in-
formation on all primary care interactions including
documented health problems, visit notes, prescriptions,Fig. 1. Drug exposure. Graphic representation of the drug by day maand records of specialty referrals, as well as information
on laboratory results, hospitalizations, and death. The
CPRD includes more than 5 million active patients and
around 600 primary care practices. Patients were included
if their records met minimum quality standards and there
were no gaps in registration.
2.3. Drug exposure
2.3.1. International data mapping
Approved oral hypoglycemics in the following thera-
peutic classes were identified in each country from the
federal regulatory agency: thiazolidinediones, sulfonyl-
ureas, biguanides, alpha glucosidase inhibitors, and DPP-
IV inhibitors. Drugs from each country were mapped to
the World Health Organization (WHO) Anatomical Ther-
apeutic Chemical classification system [47], and WHO-
defined daily doses were used to calculate the percent of
the maximum adult dose that each patient was prescribed.
Insulin was also included in the identification and
mapping exercise to allow for control of confounding by
concurrent use.
2.3.2. Oral hypoglycemic exposure measurement
Electronic prescription records were the common data
available in all three countries to measure drug exposure.
In Canada, records of dispensed medications were also
available, allowing an assessment of the accuracy of using
prescription data vs. dispensed data to measure drug expo-
sure and the impact of primary medication nonadherence
on the risk of adverse events. The prescribing date, drug,
duration, and number of refills recorded in each electronic
prescription were used to create a drug by day matrix
(Fig. 1). Each individual’s exposure to oral hypoglyce-
mic(s) was characterized using time-dependent measures
of drug use for each day from the date of the first prescrip-
tion to the end of follow-up or the date of the first cardio-
vascular event, whichever came first. For each
hypoglycemic, each user was classified on each day using
a dichotomous indicator of an active prescription. A pre-
scription was considered ‘‘active’’ if a supply of medica-
tion should exist on that day according to the
prescription date and duration (including refills). Individ-
uals prescribed more than one drug concurrentlytrix used to create time-dependent measures of drug exposure.
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each drug, respectively.
Using prescription data will result in classification errors
in drug exposure if patients do not fill their prescriptions.
Quebec had data on electronic prescriptions linked to data
on dispensing. We were able to use these linked data to
determine if there were differences in the drug-outcome
relationship when drug exposure was assessed using
dispensing data as opposed to prescription data for the same
patients. We were also able to estimate the extent of
misclassification and the characteristics of the population
involved by determining the incidence and factors associ-
ated with primary nonadherence in filling the first prescrip-
tion for diabetes treatment.2.4. Adverse cardiovascular outcomes
Cardiovascular events were defined as the first date on
which an acute MI, acute coronary syndrome, or stroke
were diagnosed in the 30 months of follow-up. For each
country, we measured outcomes by retrieving electronic
medical record diagnostic codes and dates, physician
billing (United States and Canada), and hospitalization re-
cords. International Classification of Diseases (ICD) 9 and
ICD 10 codes were used in Canada and the United States.
In England, patients in the CPRD are linked to a national
registry of hospital admissions, Hospital Episode Statis-
tics (HES), where admission and discharge dates and di-
agnoses are recorded using ICD 10, whereas Read codes
are used to record diagnostic data in the CPRD (see
Online Appendix at www.jclinepi.com for Harmonized
Codes).2.5. Confounding by demographic and comorbidity
characteristics
The choice of an oral hypoglycemic may be influenced
by a patient’s overall risk, including comorbid conditions,
disease severity and complications, age and sex, as well
as the capacity to pay for medication. All these factors
may also influence treatment outcome. To create compara-
ble patient populations, we measured these patient charac-
teristics and adjusted for them in the analysis. While less
efficient than high dimension propensity score stratification
[48,49], comorbidity-specific measurement and adjustment
will produce more transparent information about the
comparability of effects for specific patient characteristics
in different countries or settings and enable evaluation of
effect modification by patient characteristics. Although oral
hypoglycemics are almost exclusively prescribed for type 2
diabetes (i.e., single indication therapy), we assessed
whether the presence or absence of a diagnostic code for
diabetes before or at the start of therapy influenced the
results.2.6. Demographic characteristics
2.6.1. Age and sex
Date of birth and sex were retrieved from the EHR de-
mographic information in the US and England cohorts
and from the administrative data in Quebec, as these data
are verified at the time of enrollment in the health plan.2.6.2. Socioeconomic status
Financial resource capacity (household income, employ-
ment status, home ownership) and education [number of
years of education, highest level of achievement (no formal
education, primary school, high school, university)] were
measured by mapping, when available, the patient’s current
postal code (Canada) or zip code (United States) to small
area aggregated census information for persons living in
the same location. These area-level data have been shown
to provide a good proxy measure of individual socioeco-
nomic status [50]. These data were not available for
England.2.7. Prior cardiovascular events
Prior events are one of the most important predictors of
future events, irrespective of treatment [51,52]. Therefore,
cardiovascular events in the year before starting oral hypo-
glycemic therapy were assessed using the same approach as
outlined for outcome assessment.2.8. Diabetes control
Insulin use during the follow-up period was measured as
a marker of diabetes control. Any insulin products and an-
alogues were included. A dichotomous indicator was used
to create a time-dependent measure of whether an individ-
ual was exposed to insulin during the follow-up period
based on the start and completion dates for respective insu-
lin prescriptions.2.9. Code-based and clinically enhanced measures of
comorbidity
Comorbid conditions that could influence the risk of a
cardiovascular event as well as drug selection and meta-
bolism were assessed using standard diagnostic codes,
ICD 9-10, and Read (see Online Appendix at www.
jclinepi.com). We also examined whether clinically
enhanced measures of comorbidity based on additional data
from the electronic medical record (e.g., laboratory results,
weight) would increase the detection and prevalence of co-
morbid conditions, and whether more accurate classifica-
tion would have an impact on the risk associated with the
risk of cardiovascular events with hypoglycemic
medications.
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Using ICD 9, ICD 10, and Read diagnostic codes, the
following comorbidities were measured: asthma, COPD,
hypertension, dementia, and cancer. Diagnostic codes were
based on data recorded in the electronic medical record
problem list as well as ICD 9 codes documented for med-
ical visits in the administrative billing data (Canada, United
States), and Read codes that are used to document clinical
care in England (see Online Appendix at www.jclinepi.
com).
2.11. Clinically enhanced measures of comorbidity
The clinically enhanced measures for each condition
were based on diagnostic data from administrative and
EMR data problem lists, as well as EMR drugs, vital signs,
and laboratory data. Each measure that was chosen was
based on literature in addition to clinical judgment
[53e56].
2.11.1. Obesity
In addition to using diagnostic codes (see Online
Appendix at www.jclinepi.com), we also measured obesity
by calculating body mass index (BMI) [57]. BMI was based
on height and weight retrieved from the respective vital
signs files in the EMRs in England and the United States.
Obesity was defined as BMI 30. We used the most recent
height and weight (or BMI) recorded in the 2 years before
the first prescription date to measure BMI. Equivalent data
were not available for the Quebec cohort.
2.11.2. Renal disease
In addition to using diagnostic codes (see Online
Appendix at www.jclinepi.com), we measured renal disease
using laboratory results, age, and sex. Enhanced measure-
ment of renal disease was defined as either a diagnostic
code or at least one glomerular filtration rate (GFR) or esti-
mated GFR below 60 or at least one creatinine level that is
above: 137 mL/min for males and 128 mL/min for females
in the year before the first oral hypoglycemic prescription.
2.11.3. Hyperlipidemia
In addition to using diagnostic codes (ICD 9 272; ICD
10 E78), we measured hyperlipidemia by using prescrip-
tions for lipid-lowering medication in the year before the
first oral hypoglycemic prescription. Therapeutic classes
included as lipid-lowering drugs were: HMG-CoA reduc-
tase inhibitors, cholesterol absorption inhibitors, bile acid
sequestrants, nicotinic acid groups, fibric acid derivatives,
and combinations of these drugs.
2.12. Statistical analysis
Descriptive statistics were used to characterize the dia-
betes cohorts in the three countries. To assess the impact
of using prescribed vs. dispensed drugs to characterize drugexposure, the incidence of primary nonadherence (individ-
uals that did not fill their first prescription) was estimated in
the Quebec cohort, where both prescribed and dispensed
drug information were available. The drug, patient, and
physician characteristics associated with primary nonadher-
ence were estimated to characterize possible systematic
biases in drug exposure measurement using multivariate lo-
gistic regression within a generalized estimating equation
framework with an exchangeable correlation structure.
Physicians were the cluster and patient-drug combinations
were the unit of analysis.
Cox proportional hazards models were used to estimate
the risk of adverse cardiovascular events in the Quebec
cohort in relationship to primary nonadherence as well as
the two approaches to drug exposure measurement: elec-
tronic prescription data and dispensed medication data.
Both analyses provided information on whether systematic
measurement errors in drug exposure assessment would
impact the estimated risk of cardiovascular events. Primary
nonadherence was assessed as a binary exposure based on
whether the individual filled or failed to fill their initial pre-
scription in the first 12 months. To measure drug use during
follow-up, exposure was modeled as a time-dependent co-
variate, starting at the date of the first prescription. Risk
was estimated for each therapeutic category of oral hypo-
glycemic, using biguanides as the reference category. Pe-
riods where there was no drug prescription or supply
were included in the drug exposure classification as ‘‘no
drug use.’’ Patients were followed until the occurrence of
the first cardiovascular event or to the end of the follow-
up period. We conducted a sensitivity analysis to determine
if the presence or absence of a diagnosis of diabetes influ-
enced the results.
The same approach was used to evaluate the impact of
having richer clinical data vs. diagnostic codes alone to
measure clinically relevant comorbidities: obesity, lipid dis-
order, and renal disease. Differences in the prevalence of
these conditions were first estimated using the two data
sources, and then, two Cox proportional hazards models
were fit for clinical data enriched and diagnostic code alone
measures of comorbidity in each site.
The study was approved by the McGill IRB, Brigham
and Women’s ethics committee, and the Independent Scien-
tific Advisory Committee of CPRD.3. Results
Overall, 1,197 to 41,370 new users of oral hypoglycemic
were identified in each country (Table 1). The Boston
cohort of new users was younger, with only 29% of new
users being aged 65 years or older compared to 40% in En-
gland and 61.2% in Quebec, but the sex distribution was
similar. The prevalence of obesity (23.9%) and lipid disor-
der (44.0%) was substantially higher in the Boston cohort
than either the Quebec (3.2%, 10.6%) or England cohort
Table 1. Characteristics of all new users of oral hypoglycemics in the three countries
Characteristics
Boston, United States (N [ 2,346) Quebec, Canada (N [ 1,197) England (N [ 41,370)
N (%) N (%) N (%)
Demographics
Age
18e40 years 295 (12.6) 33 (2.8) 4,158 (10.0)
41e64 years 1,372 (58.5) 432 (36.1) 20,679 (50.0)
65 years 679 (29.0) 732 (61.2) 16,533 (40.0)
Sex
Female 1,156 (49.0) 619 (51.7) 18,312 (44.0)
Male 1,193 (51.0) 578 (48.3) 23,058 (56.0)
Mean (SD) Mean (SD) Mean (SD)
Income (USD) 73,167 (31,281) 62,807 (17,882) Not available
N (%) N (%) N (%)
Comorbidity
Obesity 561 (23.9) 38 (3.2) 5,224 (12.6)
Hypertension 1,194 (50.9) 596 (49.8) 17,840 (43.1)
Lipid disorder 1,033 (44.0) 127 (10.6) 6,446 (15.6)
Renal disease 72 (3.0) 20 (1.7) 4,936 (11.9)
Dementia 47 (2.0) 26 (2.2) 1,007 (2.4)
Cancer 241 (10.3) 132 (11.0) 1,510 (3.7)
Asthma 180 (7.7) 95 (7.9) 4,903 (11.9)
COPD 115 (4.9) 158 (13.2) 2,486 (5.3)
N (%) N (%) N (%)
Cardiovascular event
Previous year 127 (5.4) 52 (4.3) 1,181 (2.9)
During follow-up 132; 2.8/100 py 60; 2.2/100 py 765; 1.4/100 py
Hypoglycemics therapeutic class at start
of follow-up
Biguanides 1,938 (82.6) 1,114 (93.1) 35,921 (86.8)
Sulfonylureas 493 (21.0) 112 (9.4) 7,923 (19.2)
Other 101 (4.3) 32 (2.7) 2,298 (5.6)
Number of drugs at start of follow-up
1 drug 2,057 (87.7) 1,137 (95.0) 37,071 (89.6)
2 drugs 265 (11.3) 57 (4.8) 3,697 (9.0)
O2 drugs 24 (1.0) 3 (0.3) 602 (1.4)
Abbreviations: COPD, chronic obstructive pulmonary disease; SD, standard deviation.
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of COPD and cancer. Overall, 2.9 to 5.4% of patients had a
cardiovascular event (MI or stroke) in the year before start-
ing therapy, and the incidence of cardiovascular events dur-
ing follow-up varied from 1.4 to 2.8 per 100 person years.
The US cohort had the highest rate of cardiovascular
events. In each country, most patients were started on
monotherapy, the most common therapy being metformin
(82.6% in Boston to 93.1% in Quebec).
In the Quebec cohort, 894 of the 1,197 patients had
continuous drug insurance providing complete data on pre-
scribed and dispensed drugs during follow-up. Overall,
13% of patients who were prescribed new oral hypoglyce-
mic therapy failed to fill their prescription (Table 2). There
was a lower risk of primary nonadherence among patients
who were older (a 3% reduction in risk with each additional
year [odds ratio (OR): 0.97; P 5 0.01)], had no copayment
[a 81% reduction in risk (OR: 0.19; P! 0.001)], were pre-
scribed a biguanide [an 83% reduction in risk compared to
sulfonylureas (OR: 0.17; P ! 0.001)], and were already
taking a greater number of medications in the year beforestarting diabetes therapy [an 18% reduction in risk with
each additional medication (OR: 0.82; P ! 0.001)]. Pri-
mary nonadherence was associated with a nonstatistically
significant increase in the rate of cardiovascular events dur-
ing follow-up [4.8% vs. 2.8% for adherent patients; hazard
ratio (HR) 1.69; 95% CI: 0.57, 5.01; P 5 0.35].
In comparing the risks of cardiovascular events using
prescribed vs. dispensed information to classify drug expo-
sure, misclassification of exposure attenuated the risks
associated with the sulfonylureas (from HR: 2.83 to HR:
2.47; Table 3). In comparison, the use of prescription data
was associated with an increase in the risk associated with
periods of nondrug use. The increase in the risk of cardio-
vascular events with nondrug use based on the prescription
data was seen in all three country cohorts (Quebec HR:
1.70, 95% CI: 0.8, 3.4; England HR: 2.0, 95% CI: 1.7,
2.4; and Boston HR: 2.4, 95% CI: 1.4, 4.1; Table 4). The
mean duration of the first prescription was approximately
1 year in all three countries. Thus, compared to the
dispensing data, the risk of nondrug use would occur later
in the course of follow-up.
Table 2. The patient and drug characteristics associated with primary adherence in the Quebec cohort
Characteristics
Primary adherence status
Risk of primary nonadherence
Nonadherent Adherent
N (%) N (%)
Number of patients 116 (13.0) 778 (87.0)
Predictor N (%) N (%) OR (95% CI) P
Patient characteristics
Age
59 50 (17.7) 233 (82.3)
60e68 26 (11.4) 203 (88.7)
69e75 16 (8.2) 179 (91.8)
75 24 (12.8) 163 (87.2)
Age 0.97 (0.95e0.99) 0.01
Sex
Male 60 (13.9) 372 (86.1) Reference
Female 56 (12.1) 406 (87.9) 1.08 (0.66e1.76) 0.76
Drug insurance status
Maximum copayment 87 (16.5) 440 (83.5) Reference
Partial copayment 20 (9.3) 195 (90.7) 0.69 (0.4e1.19) 0.18
No copayment 9 (5.9) 143 (94.1) 0.19 (0.08e0.49) !0.001
Drug characteristics
Oral hypoglycemicsa
Sulfonylureas 32 (36.4) 56 (63.6) Reference
Biguanides 82 (9.9) 748 (90.1) 0.17 (0.09e0.33) !0.001
Other 12 (48.0) 13 (52.0) 0.004 (0e2.93) 0.10
Mean (SD) Mean (SD)
Drug cost (per $ increase) $10.52 (13.5) $6.82 (3.1) 1.11 (0.99e1.25) 0.08
No. of drugs in the baseline (per 1 drug
increase)
2.87 (4.6) 7.10 (5.3) 0.82 (0.75e0.89) !0.001
Abbreviations: SD, standard deviation; OR, odds ration; CI, confidence interval.
a Values correspond to number of prescriptions and not number of patients as certain individuals had more than one prescription for an oral
hypoglycemic.
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ease increased substantially when additional clinical infor-
mation was used to measure comorbidity. Obesity increased
the most from 23.9% to 72.7% in Boston and from 12.6%
to 59.7% in England. However, with the exception of En-
gland, neither diagnostic codes nor clinical measurements
of comorbidity had a significant association with the risk
of cardiovascular events during follow-up. The risk of car-
diovascular events was significantly higher for patients us-
ing sulfonylureas compared to biguanides in all three
countries and was unaffected by adjustment for code-
based or clinically enhanced measures of comorbidity.
The risk of cardiovascular events with sulfonylureas was
highest for the Boston-based cohort (HR 3.4; 95% CI:Table 3. Difference in estimated risk of cardiovascular events using prescrib
Drug exposure
Prescribed data
Drug use at start of follow-up Adjusted HR
N (%) (95% CI)
Biguanides 789 (88.3) Reference
No drug 0 (0) 1.70 (0.78e3.69) 0
Sulfonylurea 49 (5.5) 2.47 (0.85e7.22) 0
Other drugs 56 (6.2) 1.81 (0.46e5.16) 0
Abbreviations: CI, confidence interval; HR, hazard ratio.2.1, 5.5), an almost threefold greater risk than the England
cohort (HR: 1.3; 95% CI: 1.1, 1.6). Of all sulfonylurea pre-
scriptions in England, 87.6% are for gliclazide, a drug that
is not approved in the United States.4. Discussion
This study created a novel prototype of a multinational sur-
veillance system to monitor drug safety through EHRs. Using
the risk of cardiovascular disease in relationship to oral hypo-
glycemic treatment in type 2 diabetics as an exemplar, we suc-
cessfully assembled three cohorts of patients that were newly
started on therapy using EHRs in three countries. Weed vs. dispensed data for 894 patients from Quebec
Dispensed data
P
Drug use at start of follow-up Adjusted HR
PN (%) (95% CI)
699 (78.2) Reference
.18 119 (13.3) 1.36 (0.71e2.61) 0.36
.10 25 (2.8) 2.83 (0.84e9.50) 0.09
.26 51 (5.7) 0.37 (0.05e2.87) 0.34
Table 4. Difference in code vs. clinical measurements of comorbidity and its impact on the risk of cardiovascular events with oral hypoglycemics
Prevalence of comorbidities
Boston, United States (N[ 2,346) Quebec, Canada (N [ 1,197) England (N [ 41,370)
Dx code based Clinical based Dx code based Clinical based Dx code based Clinical based
N (%) N (%) N (%) N (%) N (%) N (%)
Baseline comorbidity
Obesity 561 (23.9) 1,706 (72.7) 38 (3.2) 5,224 (12.6) 24,689 (59.7)
Lipid disorder 1,033 (44.0) 1,227 (52.3) 127 (10.6) 529 (44.2) 6,446 (15.6) 19,224 (46.5)
Renal disease 72 (3.0) 748 (31.9) 20 (1.7) 4,936 (11.9) 19,539 (47.2)
Risk of a
cardiovascular
event
Code based Clinical based Code based Clinical based Code based Clinical based
HR
(95% CI) P
HR
(95% CI) P
HR
(95% CI) P
HR
(95% CI) P
HR
(95% CI) P
HR
(95% CI) P
Comorbidities
Obesity 0.9
(0.6e1.5)
0.72 1.2
(0.7e1.7)
0.43 1.2
(0.3e5.4)
0.84 1.2
(0.3e5.7)
0.81 0.9
(0.7e1.1)
0.33 0.9
(0.8e1.0)
0.12
Lipid disorder 1.3
(0.8e1.9)
0.26 1.2
(0.8e1.8)
0.40 1.4
(0.6e2.9)
0.43 1.2
(0.7e2.1)
0.49 1.2
(1.0e1.5)
0.02 0.9
(0.7e1.0)
0.04
Renal disease 1.2
(0.6e2.1)
0.64 1.1
(0.8e1.6)
0.59 0.9
(0.2e3.2)
0.84 0.8
(0.2e3.1)
0.79 0.9
(0.7e1.1)
0.27 0.8
(0.7e0.9)
0.002
Oral hypoglycemics
No drug 2.4
(1.4e4.1)
0.002 2.3
(1.4e4.0)
0.002 1.7
(0.8e3.4)
0.14 1.7
(0.9e3.5)
0.13 2.0
(1.7e2.4)
!0.001 2.0
(1.7e2.4)
!0.001
Sulfonylureas
only
3.2
(1.9e5.3)
!0.001 3.4
(2.1e5.5)
!0.001 2.8
(1.2e6.8)
0.022 2.9
(1.2e6.9)
0.02 1.3
(1.0e1.6)
0.03 1.3
(1.1e1.6)
0.05
Biguanides
only
Reference Reference Reference Reference Reference Reference
Abbreviations: HR, hazard ratio; CI, confidence interval.
Notes: 1. Multivariate Cox Proportional hazards models were estimated separately for each country and for code vs. clinically enhanced comor-
bidities. Each model was adjusted for age, sex, comorbidities, insulin use, and prior cardiovascular events.
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drug use measures to a common international standard and
used the information assets in one country to estimate the
extent of bias in drug exposure and comorbiditymeasurement.
In each country, we showed the expected results: an in-
crease in the risk of cardiovascular events with sulfonyl-
ureas compared to metformin. Risk estimates were within
the CIs of those reported previously using both administra-
tive data and EHRs [38e46].
One unexpected finding was that there were substantial
differences in the magnitude of the risk among countriesd
an almost threefold greater risk of cardiovascular events
with the sulfonylureas in the US cohort compared to En-
gland that appear to be related to health system effects on
prescribing practices. Although differences in risk may
represent unmeasured confounding, a more plausible expla-
nation is the sulfonylureas prescribed in the two countries.
England almost exclusively used gliclazide as the sulfonyl-
urea of choice. In the United States, gliclazide is not
approved, and glipizide (58.7%) and glyburide (38.0%) ac-
count for 97% of the sulfonylurea prescriptions. Both ani-
mal and human studies [43,58,59] consistently show that
the risk of cardiovascular events with gliclazide is no
different than with the metformin, whereas with all other
sulfonylureas, there is a significant increase in the risk of
cardiovascular events. The selective affinity of gliclazide
for K ATP channels in the pancreatic beta cells rather than
the heart and smooth muscle is thought to be responsible forthese differences in risk [59]. These findings highlight the
value of a multinational surveillance system that can mine
natural experimental differences in health systems and pop-
ulations such as drug approval, prescribing practices, and
case mix to more rapidly illuminate important attributes
of drug risk and benefit that require further investigation.
One of the benefits of multinational surveillance is that
investigators are able to use assets in one country to esti-
mate potential sources of bias. In this study, the Canadian
site was used to evaluate the potential limitations of using
prescription data to measure drug exposure. We showed
that approximately 1 in 10 patients who are newly started
on an oral hypoglycemic do not fill the initial prescription
that primary noncompliance was differential across thera-
peutic classes and was most strongly associated with health
systemerelated policies that define the amount the patient
will have to pay for the drug. Drug costs and patient
cost-sharing policies within a country or jurisdiction have
been shown to influence primary and secondary adherence
to therapy [60e63]. As a result, measurement error will be
introduced, particularly for higher cost new drug therapies
that will attenuate the estimated risk of drug use in post-
market surveillance studies. In this study, the risk of cardio-
vascular events with the use of sulfonylureas was greater
when dispensing data were used to measure drug exposure
compared to prescribing data, from HR 2.49 to HR 2.83, a
13% increase in risk. When dispensing data are not avail-
able, the positive predictive value for a subset of the
109R. Tamblyn et al. / Journal of Clinical Epidemiology 77 (2016) 101e111population from a country with comparable costs and co-
payment policies could be used to adjust for the underesti-
mate of risk. Abrahamowicz has outlined several
approaches that could be used to adjust for these biases
[64].
Periods of nondrug use were associated with a signifi-
cant increase in risk of cardiovascular events in all three
countries, but only when prescribing data were used to
measure drug exposure. Failure to return to obtain subse-
quent prescriptions may represent medication nonadher-
ence, which in diabetes has been associated with a 41%
increase in inpatient costs; findings that are consistent with
our study, which also shows a risk of cardiovascular events
with nonadherence [65]. Once drug exposure measurement
was corrected for actual drug supply using dispensing data,
there was a substantial reduction in the risk. This is likely
due to a mix of effects that include both the healthier subset
of newly treated diabetics that did not fill their first pre-
scription (that are never included in medication adherence
studies), as well as those that were less adherent after start-
ing therapy.
We found a substantial, but not surprising, increase in
the prevalence of comorbidity when measurement was
based on clinical data in addition to diagnostic data. This
was particularly true for obesity and renal disease where
there was a twofold to threefold increase in prevalence once
additional clinical data were considered. These results un-
derline the value of increasing capacity to use EHRs in
pharmacosurveillance research. Although better measure-
ment of comorbidity did not have an impact on the esti-
mated risk of oral hypoglycemics, they were not strong
confounders for adverse cardiovascular events in relation-
ship to drug exposure. Enrichment of other, more signifi-
cant, confounders in another setting may well impact the
results more profoundly.
One of the challenges in using EHR data from different
countries is the differences in classification systems used
to code health problems and medications. Fortunately, most
EHR-based prescribing systems document the drug pre-
scribed using standardized text strings. These standardized
text strings can be easily mapped to the WHO master list
to harmonize drug exposure measures [47]. In contrast,
dosing information is typically entered as free text, and
text-mining algorithms need to be developed to extract in-
formation about the dose per administration and the fre-
quency per day. Some progress is being made in
developing accurate extraction methods for drug dosing data
[66]. Diabetes and other comorbidities that were relevant to
the risk of cardiovascular disease were identified using ICD
9, ICD 10 (United States and Canada), and Read codes (En-
gland). Ultimately, the aim is to use SNOMED CT as the
classification system for EHRs as it provides the refinement
needed for clinical documentation and ICD 10 for adminis-
trative documentation. Approximately 69% of problems can
be equivalently identified by both systems [67]. Differences
in the prevalence of comorbidities in the differentjurisdictions noted in this study may be related to the lack
of precision of the coding systems, local diagnostic prac-
tices, or true differences in population rates. Future research
should extend recommended approaches for validating diag-
noses in EHR systems to support international investigation
[68].
There are a number of limitations to consider in this
study. First, the estimation of risk by therapeutic class
masked important differences that may exist in the cardio-
vascular risk of different sulfonylureas; however, the almost
complete nesting of sulfonylureas used in the respective
countries made it impossible to separate drug from country
effects. Second, the smaller sample size in the Quebec
cohort compromised the power to identify clinically mean-
ingful associations. Third, although prior studies have pro-
vided evidence of the validity of diagnostic data within the
EHRs used in this study [68e74], we do not know whether
there was equivalent ascertainment of comorbidities across
jurisdictions.
In summary, a multinational surveillance system that
builds on international efforts to deploy EHRs has the po-
tential to produce more timely information about drug
safety and effectiveness than traditional approaches
because millions of new users can be monitored worldwide,
and differential effects by race, sex, and clinical subgroups
can be more rapidly detected. We have shown that this
approach is feasible, and the results are validated by sub-
stantial existing evidence of a greater risk of cardiovascular
events with sulfonylureas. Multiple countries also provided
unique opportunities to estimate potential sources of bias
and identify health system characteristics and prescribing
practices can modify drug safety and effectiveness.Supplementary Data
Supplementary data related to this article can be found at
http://dx.doi.org/10.1016/j.jclinepi.2016.03.033.References
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